Medicine & Life Sciences
Melanoma
100%
pembrolizumab
66%
Neoplasms
30%
Survival
23%
T-Lymphocytes
18%
Therapeutics
17%
Ipilimumab
16%
Neoplasm Metastasis
16%
Immunotherapy
15%
Drug Therapy
11%
Ligands
11%
Radiosurgery
11%
Safety
11%
Renal Cell Carcinoma
11%
Temozolomide
10%
Uveal melanoma
10%
Everolimus
9%
Bevacizumab
9%
Lymphoproliferative Disorders
9%
Progression-Free Survival
8%
Response Evaluation Criteria in Solid Tumors
8%
glucopyranosyl lipid-A
7%
Sex Characteristics
7%
Immunity
6%
Lung Neoplasms
6%
ADAM17 Protein
6%
Programmed Cell Death 1 Receptor
6%
trametinib
6%
B-Lymphocytes
6%
Cisplatin
6%
Carboplatin
5%
Lymphocytes
5%
Carbonic Anhydrase IX
5%
Confidence Intervals
5%
Brain Neoplasms
5%
Vemurafenib
5%
platelet-derived growth factor A
5%
Mantle-Cell Lymphoma
5%
Hematinics
5%
Testicular Germ Cell Tumor
5%
Galectins
5%
Extracellular Vesicles
5%
Death Domain Receptors
5%
Paclitaxel
5%
Immunomodulation
5%
Periodicity
5%
Antibodies
5%
B-Cell Chronic Lymphocytic Leukemia
5%